Patients

People living with cancer need new advances. Unleash the possibilities.

Patients with cancer are looking to us to develop solutions and create new paths to cancer breakthroughs.

We focus on the science –
and the people

We focus on both solid tumors and hematological malignancies. We know the need is great, which is why we scrutinize promising molecules from every angle to unlock their full potential with the goal of developing transformative therapies that enable patients with cancer to lead better, longer lives.

Desmoid tumors are rare, aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. There are currently no FDA-approved systemic therapies for the treatment of desmoid tumors.
About 30-50% of people with neurofibromatosis type 1 (NF1) develop plexiform neurofibromas (PN), which are peripheral nerve sheath tumors that can cause significant pain, disfigurement, and functional impairment. NF1-PN can transform into malignant peripheral nerve sheath tumors (MPNST), a diagnosis that has a 12-month survival rate of under 50%.

Expanded access & compassionate use

What are the treatment options?

Expanded access, which is also sometimes called “compassionate use,” is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational medical product for treatment outside of a clinical trial setting, when no comparable or satisfactory alternative therapeutic options are available and prior to its commercial availability.

Does SpringWorks have an expanded access / compassionate use program?

In cases when a patient may not qualify for a clinical trial, there may be no trials available, or a patient has exhausted all available treatment options, SpringWorks may be able to provide access to eligible patients through our Expanded Access Program.

How
it works

Requests for access to a SpringWorks investigational therapy must be made voluntarily by the patient’s treating physician. Requests cannot be made directly by an individual patient or a patient’s parent/legal guardian or caregiver.

To request expanded access or compassionate use, physicians in the United States should send an email to usmapcoordinators@clinigengroup.com. Physicians from outside of the United States should email medicineaccess@clinigengroup.com.

Patient advocacy groups

Its mission is to aggressively fund research to accelerate development of therapies for desmoid tumors.
Its mission is to drive research, expand knowledge and advance care for the NF community.
Its mission is to find treatments and a cure for neurofibromatosis by promoting scientific research.